Microenvironment-related predictive markers of the therapeutic effectiveness of eribulin in patients with locally advanced or metastatic breast cancer: pilot study
Background. Triple negative breast cancer has no specific treatment sites for chemotherapy and is unfavorable in terms of prognosis. One of the drugs widely used in this cohort of patients is eribulin, which in addition to its antimitotic effect has an effect on the tumor microenvironment. The searc...
Main Authors: | L. A. Tashireva, N. O. Popova, V. V. Alifanov, V. E. Goldberg, E. I. Kovalenko, E. V. Artamonova, A. G. Manikhas, D. M. Ponomarenko, N. V. Levchenko, E. I. Rossokha, S. Yu. Krasilnikova, M. A. Zafirova, V. M. Perelmuter |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2022-01-01
|
Series: | Опухоли женской репродуктивной системы |
Subjects: | |
Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/895 |
Similar Items
-
B Lymphocytes Are a Predictive Marker of Eribulin Response and Overall Survival in Locally Advanced or Metastatic Breast Cancer: A Multicenter, Two-Cohort, Non-Randomized, Open-Label, Retrospective Study
by: Liubov A. Tashireva, et al.
Published: (2022-06-01) -
Eribulin-trastuzumab combination in HER2-positive metastatic breast cancer: updated results from a Russian observational study
by: E. I. Kovalenko, et al.
Published: (2021-12-01) -
Eribulin in Metastatic Breast Cancer: Actual Clinical Practice
by: A. V. Sultanbaev, et al.
Published: (2023-04-01) -
Prognostic significance of neutrophil to lymphocyte ratio in patients with metastatic breast cancer on the background of eribulin therapy
by: A. V. Zyuzyukina, et al.
Published: (2022-09-01) -
Efficacy of Eribulin in Soft Tissue Sarcomas
by: Edward Phillips, et al.
Published: (2022-03-01)